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Abstract: Aim: We aimed to examine the alterations of the insulin signaling pathway, autophagy,
nitrative stress and the effect of vitamin D supplementation in the liver and ovaries of vitamin D
deficient hyperandrogenic rats. Methods: Female Wistar rats received eight weeks of transdermal
testosterone treatment and lived on a low vitamin D diet (D–T+). Vitamin D supplementation
was achieved by oral administration of vitamin D3 (D+T+). Sham-treated (D+T–) and vitamin D
deficient animals (D–T–) served as controls. (N = 10–12 per group). Results: D–T+ animals showed
decreased LC3 II levels in the liver and increased p-Akt/Akt and p-eNOS/eNOS ratios with decreased
insulin receptor staining in the ovaries. Vitamin D supplementation prevented the increase of Akt
phosphorylation in the ovaries. Vitamin D deficiency itself also led to decreased LC3 II levels in
the liver and decreased insulin receptor staining in the ovaries. D–T+ group showed no increase
in nitrotyrosine staining; however, the ovaries of D–T– rats and the liver of D+T+ animals showed
increased staining intensity. Conclusion: Vitamin D deficiency itself might lead to disrupted ovarian
maturation and autophagy malfunction in the liver. Preventing Akt phosphorylation may contribute
to the beneficial effect of vitamin D treatment on ovarian function in hyperandrogenism.
Keywords: hyperandrogenism; vitamin D; polycystic ovary syndrome (PCOS); insulin resistance;
autophagy; oxidative stress
1. Introduction
Polycystic ovary syndrome (PCOS) is a complex endocrine disease of fertile women, its estimated
occurrence is between 5–15%. PCOS involves hyperandrogenism and ovulatory dysfunction leading
to infertility or an increased rate of miscarriage. Furthermore, it is associated with a variety of other
comorbidities including obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic fatty liver disease
(NAFLD) [1].
Besides the characteristic hyperandrogenism, vitamin D deficiency is shown to commonly be
associated with PCOS [2,3]. Both vitamin D deficiency [4] and hyperandrogenism may contribute to
the development of insulin resistance (IR) observed in women with PCOS, although the underlying
mechanism of IR seems to be different [5]. Vitamin D deficiency also plays role in the ovarian
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dysfunction of these patients [6]. The beneficial effect of vitamin D supplementation in PCOS has
been previously shown on insulin resistance, lipid metabolism and accumulation as well as on ovarian
function, however the results of randomized controlled trials are controversial and the underlying
molecular mechanisms are not fully understood [6–9].
Alteration in oxidative stress and cell death pathways are proposed to play important role in the
development of PCOS [10]. Recent studies also stipulate that inadequate regulation of autophagy in
ovarian and hepatic tissues may also contribute to the pathogenesis of the disease and the related
insulin resistance [11]. Inhibition of autophagy pathways as potential underlying mechanisms in
skeletal muscle IR was described in an animal model of PCOS [12]. Another study reported the
attenuating effect of vitamin D on cardiac abnormalities in a PCOS model by normalizing autophagy
function in cardiomyocytes [13]. However, it has not been thoroughly investigated how vitamin D
deficiency may alter hepatic and ovarian autophagy in PCOS.
In the present study, we aimed to examine the effect of vitamin D supplementation on insulin
receptor signaling, autophagosomal turnover and nitrative stress in the liver and the ovaries in a
vitamin D deficient hyperandrogenic rat model of PCOS.
2. Materials and Methods
2.1. Animals
The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the
US National Institutes of Health (8th edition, 2011) and the EU conform Hungarian Law on Animal
Care (XXVIII/1998). The institutional Animal Care Commission approved the study protocol (IRB:
8/2014 PEI/001/1548-3/2014).
A total number of 46 female Wistar rats (Charles River Ltd., AnimaLab, Vác, Hungary) aged
21–28 days, weighing 100–140 g were divided into four groups as the following: Hyperandrogenic
vitamin D deficient group (D–T+, n = 11); hyperandrogenic vitamin D supplemented group (D+T+,
n = 12); vitamin D deficient group (D–T–, n = 11) and vitamin D supplemented group (D+T–, n = 12).
To induce hyperandrogenism, an 8-week-long transdermal testosterone treatment was
implemented by applying 0.0333 mg/g of Androgel (50 mg/5 mL gel by Lab. Besins International
S.A., Monaco) 5 times a week on a previously shaved 3 × 3 cm area on the back of the animals.
Transdermal testosterone treatment was calculated to reach target androgen levels of previous PCOS
models considering the bioefficacy of the transdermal application [14–18].
Vitamin D depleted animals were fed the Vitamin D Free Lab Rat/Mouse Chow (ssniff Spezialdiaten
GmbH, Soest, Germany) containing less than 5 IU/kg of vitamin D3, whereas supplemented animals
received a regular chow containing 1000 IU/kg of vitamin D. The supplemented animals also received
additional oral vitamin D (Vigantol (cholecalciferol) 20,000 IU/mL, Merck/Merck Serono, Darmstadt,
Germany) as the following: 500 IU on the second week of treatment as a saturation dose, and weekly
140 IU/100 g on the fifth, sixth and seventh week of the treatment. The previously calculated amount
of Vigantol was measured with micropipettes and administered to the animals using a gavage cannula.
Target serum 25-OH-cholecalciferol levels (20–50 ng/mL) were adjusted to the currently accepted
human vitamin D supplementation guidelines [19,20]. Figure 1 summarizes the chronic treatment of
different groups week by week.
The animals were supplied with appropriate rat chow and tap water ad libitum. Rats were housed
at constant room temperature (22 ± 1 ◦C) in 12 h/12 h light–dark cycle.
On the 8th treatment week, animals were sacrificed in Nembutal anaesthesia (45 mg/kg
intraperitoneal). Testosterone-treated animals had no estrus cycles; D+T– and D–T– animals were
selected regardless of estrus cycle phase. Liver and ovarian tissue samples were harvested after
whole-body perfusion, snap frozen in liquid nitrogen and stored at −80 ◦C or fixed in formaldehyde
(4%) phosphate buffered saline solution. Fixed tissues were embedded in paraffin and histological
sections (5 µm) were prepared.
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Figure 1. Timeline of chronic treatment in different treatment groups. Adolescent Wistar rats were 
divided into four groups—half of the animals received transdermal testosterone treatment (0.0333 
mg/body weight grams 5 times weekly) for 8 weeks, while another half did not receive androgens. 
Half of the animals in each group were fed low vitamin D chow while the other half received adequate 
vitamin D supplementation (weekly 1.4 NE/body weight grams per os on the 3rd, 4th, 5th, 6th, and 
7th week after a 500 NE saturation on the 2nd week). On the 6th treatment week, an oral glucose 
tolerance test (OGTT) was performed. On the 8th treatment week, the animals were sacrificed, and 
their tissues were kept at −80 °C until further studies. 
2.2. Immunohistochemistry 
Immunohistochemistry was performed on paraffin embedded tissue sections of the liver and 
ovaries against insulin receptor beta (IRβ), vitamin D receptor (VDR) and 3-nitrotyrosine (NT) by 
BenchMark ULTRA Automated IHC/ISH slide staining system (Ventana Medical Systems, Inc., 
Tucson, AZ, USA) using monoclonal mouse anti-IRβ (Santa Cruz Biotechnology, Dallas, TX, USA), 
polyclonal rabbit anti-VDR and anti-NT (Abcam, Cambridge, UK) antibodies. Visualization of 
specific labeling with diaminobenzidine (DAB) as colored substrate and hematoxylin counterstaining 
was achieved by UltraView Universal DAB Detection Kit (Ventana Medical Systems, Inc.). 
Microscopic images of immunostained tissue sections were taken by Zeiss Axio Imager system (Zeiss, 
Oberkochen, Germany). Non-calibrated optical density of specific staining was measured by ImageJ 
software (NIH, Bethesda, MA, USA). 
2.3. Western Blotting 
Tissue samples were homogenized in radioimmunoprecipitation assay buffer (Cell Signaling, 
Danvers, MA, USA) supplemented with protease inhibitor (Roche, Basel, Switzerland) and sodium 
Figure 1. Timeline of chronic treatment in different treatment groups. Adolescent Wistar rats
were divided into four groups—half of the animals received transdermal testosterone treatment
(0.0333 mg/body weight grams 5 times weekly) for 8 weeks, while another half did not receive
androgens. Half of the ani als in each group were fed low vitamin D chow while the other half
received adequate vitamin D supplementation (weekly 1.4 NE/body weight grams per os on the 3rd,
4th, 5th, 6th, and 7th week after a 500 NE saturation on the 2nd week). On the 6th treatment week,
an oral glucose tolerance test (OGTT) was performed. On the 8th treatment week, the animals were
sacrificed, and their tissues were kept at −80 ◦C until further studies.
2.2. Immunohistochemistry
I munohistochemistry was performed on paraffin embedded tissue sections of the liver and
ovaries against insulin receptor beta (IRβ), vitamin D receptor (VDR) and 3-nitrotyrosine (NT) by
BenchMark ULTRA Automated IHC/ISH slide staining system (Ventana Medical Systems, Inc., Tucson,
AZ, USA) using monoclonal mouse anti-IRβ (Santa Cruz Biotechnology, Dallas, TX, USA), polyclonal
rabbit anti-VDR and anti-NT (Abcam, Cambridge, UK) antibodies. Visualization of specific labeling
with diaminobenzidine (DAB) as colored substrate and hematoxylin counterstaining was achieved
by UltraView Universal DAB Detection Kit (Ventana Medical Systems, Inc.). Microscopic images of
immunostained tissue sections were taken by Zeiss Axio Imager system (Zeiss, Oberkochen, Germany).
Non-calibrated optical density of specific staining was measured by ImageJ software (NIH, Bethesda,
MA, USA).
2.3. Western Blotting
Tissue samples were homogenized in radioimmunoprecipitation assay buffer (Cell Signaling,
Danvers, MA, USA) supplemented with protease inhibitor (Roche, Basel, Switzerland) and sodium
fluoride (Sigma, St Louis, MO, USA). Protein concentration of the homogenates was measured by
BCA kit (Thermo Scientific, Waltham, MA, USA). An equal amount of protein (40 µg) was mixed with
Pierce™ Lane Marker Reducing Sample Buffer (Thermo Scientific), loaded and separated in a 4–20%
precast Tris-glycine SDS polyacrilamide gel (Bio-Rad, Hercules, CA, USA). Proteins were transferred
onto a polyvinylidene difluoride membrane (Bio-Rad) at 200 mA, overnight. Proper transfer was
visualized with Ponceau staining (Sigma). Membranes were blocked with 5% bovine serum albumin
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(BSA; Santa Cruz Technology) or with 5% Blotting-Grade Blocker in Tris-buffered saline containing
0.05% Tween-20 (0.05% TBS-T; Sigma) at room temperature for 2 h. Membranes were probed with
primary antibodies purchased from Cell Signaling overnight at 4 ◦C (LC3A/B—#4108; phospho-S6
[Ser235/236]—#2211; S6—#2317; phospho-Akt [Ser473]—#9271; Akt—#9272; phospho-eNOS—#9571;
eNOS—#9572; GAPDH—#5174), and with corresponding HRP-conjugated secondary antibodies (Cell
Signaling) for 2 h at room temperature. Signals were detected with an enhanced chemiluminescence
kit (Bio-Rad) by Chemidoc XRS+ (Bio-Rad). Antibodies detecting phosphorylated epitopes were
removed with Pierce Stripping Buffer (Thermo Scientific) before incubation with antibodies detecting
the total protein.
2.4. Statistical Analysis
Effects of testosterone treatment and vitamin D status were evaluated by two-way ANOVA using
Tukey’s post-hoc test by Prism 5 (GraphPad, GraphPad Software, San Diego, CA, USA). In case of
significant interaction between the effects of the two treatments (NT staining), one-way ANOVA with
Tukey’s post hoc test was performed. p < 0.05 was uniformly accepted as the threshold for statistical
significance. Data are shown as mean ± SEM.
3. Results
3.1. Chracteristics of PCOS in Our Model
The physiological parameters describing our model are discussed in detail in Hadjadj L et al.
(2018) [5]. Briefly, testosterone treatment resulted in a 10-fold increase in testosterone and a 5-fold
increase in DHT serum levels while non-treated animals had normal androgen levels. Vitamin D
supplementation resulted in adequate serum 25-OH-vitamin D levels (target range: 20–50 ng/mL)
whereas animals kept on a vitamin D free diet showed severe vitamin D deficiency (serum levels under
10 ng/mL) [19]. Testosterone treatment led to an elevated number of smaller, mostly primordial follicles
that is typical for PCOS, and reduced serum progesterone levels caused by missing luteinisation.
We detected an emerging insulin resistance with testosterone treatment elevating glucose levels and
vitamin D deficiency elevating insulin levels and leading to a higher computed HOMA-IR (Homeostatic
Model of Insulin Resistance) value following OGTT.
3.2. Alterations of Insulin Receptor Signaling and Autophagy in the Liver
Vitamin D deficient hyperandrogenic animals showed reduced LC3 II levels reflecting
decreased autophagosomal turnover. Vitamin D supplementation failed to ameliorate this change.
However, vitamin D deficiency itself also led to decreased LC3 II levels (Figure 2D).
Akt phosphorylation was not altered in any of the diseased groups (Figure 2A). Besides Akt
phosphorylation eNOS phosphorylation was also unaltered by testosterone treatment or vitamin D
deficiency, suggesting unchanged insulin signaling (Figure 2A,B).
On the other hand, S6 protein phosphorylation was increased by testosterone treatment that may
reflect a direct proliferative effect of testosterone (Figure 2C).
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Figure 2. Alterations in insulin signaling pathway and autophagy in the liver. (A) Akt 
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phosphorylation in the liver. (D) LC3 II formation in the liver. LC3 II levels normalized to GAPDH. 
Data are presented as mean ± SEM. Two-way (factor 1—vitamin D supplementation vs. vitamin D 
deficiency; factor 2—control vs. testosterone treatment) ANOVA; t: p < 0.05 control vs. testosterone 
treatment; Tukey’s post hoc test (comparison of experimental groups), * p < 0.05 vs. D+T– group, ** p 
< 0.01 vs. D+T– group; n = 5–8 in each group. 
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We detected a significantly increased p-Akt/Akt and p-eNOS/eNOS ratio in the ovarian samples 
of vitamin D deficient hyperandrogenic animals. Vitamin D supplementation prevented the elevation 
of p-Akt/Akt ratio, but not the p-eNOS/eNOS ratio. Vitamin D deficiency itself had no effect on these 
parameters (Figure 3A,B). Having examined the total area of the ovaries, we found no difference 
between study groups in insulin receptor beta (IRβ) immunostaining. Literature suggests difference 
in IRβ staining of follicles when in various stages of maturation [21]. According to our results, in the 
primordial, primary and secondary follicles, there was no difference in IRβ positivity. On the other 
hand, among the large antral follicles, there was a significantly decreased IRβ immunostaining in all 
experimental groups (D–T–, D+T+, D–T+) compared to sham treated controls (D+T–) (Figure 3C). The 
ratio of p-S6/S6 and the level of LC3 II was not influenced by either treatment (Figure 3D,E). 
Figure 2. Alterations in insulin signaling pathway and autophagy in the liver. (A) Akt phosphorylation
in liver tissue. (B) eNOS phosphorylatio in liver tissue. (C) Protein S6 phosphorylation in the liver.
(D) LC3 II formation in th liver. LC3 II levels normalized to GAPDH. Data are pr sented as m an ±
SEM. Tw -w y (factor 1— itamin D supple entatio vs. vitamin D defici ncy; factor 2—control vs.
testoste one tr atment) ANOVA; t: p < 0.05 control vs. testostero e treatment; Tukey’s post hoc test
(comparison of experime tal groups), * p < 0.05 vs. D+T– group, ** p < 0.01 vs. D+T– group; n = 5–8 i
each group.
3.3. Alterations of Insulin Receptor Signaling and Autophagy in the Ovaries
We detected a significantly increased p-Akt/Akt and p-eNOS/eNOS ratio in the ovarian samples
of vitamin D deficient hyperandrogenic animals. Vitamin D supplementation prevented the elevation
of p-Akt/Akt ratio, but not the p-eNOS/eNOS ratio. Vitamin D deficiency itself had no effect on these
parameters (Figure 3A,B). Having examined the total area of the ovaries, we found no difference
between study groups in insulin receptor beta (IRβ) immunostaining. Literature suggests difference in
IRβ staining of follicles when in various stages of maturation [21]. According to our results, in the
primordial, primary and secondary follicles, there was no difference in IRβ positivity. On the other
hand, among the large antral follicles, there was a significantly decreased IRβ immunostaining in all
experimental groups (D–T–, D+T+, D–T+) compared to sham treated controls (D+T–) (Figure 3C).
The ratio of p-S6/S6 and the level of LC3 II was not influenced by either treatment (Figure 3D,E).
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experimental groups) * p < 0.05 vs. D+T– group among large follicles, ** p < 0.01 vs. D+T– group
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3.4. Nitrative Stress in the Liver and in the Ovaries
We found significantly increased density of 3-nitrotyrosine (NT) staining in the liver tissue of
the vitamin D supplemented hyperandrogenic (D+T+) group. However, in the ovaries, increased
staining was observed in the vitamin D deficient group (D–T–). On the other hand, the vitamin D
deficient hyperandrogenic rats (D–T+) did not show increased nitrative stress in the examined tissues
(Figure 4A,B).
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Figure 4. Nitrative stress in the liver and in the ovaries. (A) Immunohistochemical staining of liver
tissue with anti-NT antibody. (B) Immunohistochemical staining of ovarian tissue with anti-NT
antibody. Data are presented as mean ± SEM. One-way ANOVA with Tukey’s post hoc test. * p < 0.05
vs. D+T– group, # p < 0.05 vs. D–T+ group, ˆ p < 0.05 vs. D–T– group; n = 5–8 in each group.
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3.5. Changes of Vitamin D Receptor Immunostaining in the Liver and the Ovaries
In vitamin D deficient hyperandrogenic animals, increased VDR specific staining intensity was
observed in both hepatic and ovarian tissues. Vitamin D supplementation prevented this change
(Figure 5A,B).Biomolecules 2019, 9, x FOR PEER REVIEW 9 of 15 
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Figure 5. Vitamin D receptor density in the liver and in the ovaries. (A) Immunohistochemical staining
of liver tissue with anti-VDR antibody. (B) Immunohistochemical staining of ovarian tissue with
anti-VDR antibody. Data are presented as mean± SEM. Two-way (factor 1—vitamin D supplementation
vs. vitamin D deficiency, factor 2—control vs. testosterone treatment) ANOVA, t: p < 0.05 control
vs. testosterone treatment, ttt: p < 0,001 control vs. testosterone treatment, d: p < 0.05 vitamin D
supplementation vs. vitamin D deficiency, dd: p < 0.01 vitamin D deficiency vs. vitamin D deficiency;
Tukey’s post hoc test (comparison of experimental groups), ** p < 0.01 vs. D+T– group,*** p < 0.001 vs.
D+T– group, ˆ p < 0.05 vs. D–T– group; n = 5–8 in each group.
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4. Discussion
The risk of NAFLD that is strongly linked to metabolic syndrome is known to be increased
in PCOS due to elevated androgen levels and insulin resistance [22]. The role of autophagy in the
pathogenesis of NAFLD has been extensively studied recently. Decreased autophagosomal turnover is
shown to play important role in the impairment of lipid droplet degradation in the liver [23]. In our
vitamin D deficient hyperandrogenic rat model, we found decreased LC3II levels indicating reduced
autophagosomal turnover in the liver. This may suggest the involvement of decreased autophagy in
the increased risk of NAFLD in PCOS.
Increased Akt/mTOR signaling may contribute to the progression of steatosis in case of
higher insulin levels in insulin resistance by inhibiting autophagy [23]. On the other hand,
in our vitamin D deficient hyperandrogenic rat model, the decreased autophagosomal turnover
characterized by decreased LC3II levels was not accompanied by increased Akt phosphorylation.
Therefore, the decreased autophagosomal turnover was probably not due to increased Akt signaling.
Vitamin D was previously shown to attenuate hepatic steatosis by inducing autophagy [24].
However, in our experiments, vitamin D supplementation failed to prevent the reduction in LC3II
levels during testosterone treatment. On the other hand, vitamin D deficiency itself without
hyperandrogenism resulted in reduced LC3II levels. The decreased LC3II levels was not accompanied
with increased AKT phosphorylation in this case either, suggesting an Akt independent mechanism
of vitamin D action. One possible mechanism is the upregulation of autophagy-related 16-like 1
(ATG16L1) gene that was shown to play role in the autophagy inducing effect of vitamin D in mice
fed with high fat diet [24]. The characterization of mechanisms responsible for decreased hepatic
autophagy in hyperandrogenism and vitamin D deficiency, however, requires further investigations.
Besides Akt phosphorylation eNOS phosphorylation was also unaltered by testosterone treatment
or vitamin D deficiency, suggesting unchanged insulin signaling. Vitamin D deficient animals of the
present rat model are characterized by elevated insulin levels [5] where unaltered Akt and eNOS
phosphorylation may reflect insulin resistance in the liver.
At the same time, in our experiments, S6 protein phosphorylation was increased by testosterone
treatment. This may reflect a direct proliferative effect of testosterone that can also contribute to the
development of NAFLD independently from insulin signaling pathway [25]. It has also been previously
shown that liver specific depletion of the p70 S6 kinase protect against hepatic steatosis, suggesting the
role of S6 phosphorylation in the development of NAFLD. The activation of the mTOR/S6 pathway in
the liver may also contribute to the development of systemic insulin resistance [26].
In contrast to the liver, elevated Akt and eNOS phosphorylation was found in the ovarian tissues
of vitamin D deficient hyperandrogenic rats. Low-dose dihydrotestosterone treatment in mice also led
to similar changes in Atk phosphorylation; p-Akt/Akt ratio was increased in the ovaries, but not in
the liver [27]. Altered Akt activation disturbs dominant follicle selection, as by the time of selection,
dominant follicle normally have significantly elevated p-Akt/Akt ratio compared to subordinate
follicles [28]. The increased activity of PI3K/Akt pathway may also contribute to the development of
polycystic ovaries, as the overactivation of this pathway can lead do impaired follicle development and
the appearance of numerous immature follicles and may contribute to cyst formation [29]. Vitamin D
supplementation managed to prevent the increase in Akt phosphorylation that may play a role in the
beneficial effect of vitamin D supplementation for follicular function.
On the other hand, eNOS phosphorylation was not prevented by vitamin D supplementation
in hyperandrogenic rats. Whereas the acute activation of eNOS by testosterone through the
phosphatidylinositol 3 kinase (PI3K)/Akt pathway is well characterized [30], the chronic effect of
androgens on eNOS phospholytaion is rarely examined [31]. In penile tissues, increased eNOS activity
was found after elevation of serum testosterone levels by chronic treatment of icariin [32].
IRβ can be found on granulosa and theca cells in the ovaries [33] and its expression changes during
folliculogenesis; upregulation of IRβ can be observed during maturation and gets prominent in tertiary
antral follicles [34]. This characteristic upregulation was not present in hyperandrogenic vitamin
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D deficient rats, however, vitamin D supplementation failed to prevent this effect of testosterone
treatment. Vitamin D deficiency itself resulted in significant reduction of IRβ immunostaining of
tertiary follicles. Disturbance in the IRβ expression in PCOS [21] has been associated with receptor
downregulation due to hyperinsulinaemia. Supporting this theory, in our study, the vitamin D-deficient
rats had elevated insulin levels compared to vitamin D-supplemented groups. However, D+T+ animals
had higher plasma glucose levels without hyperinsulinemia, they also showed lower IRβ density in
large follicles. The increased Akt phosphorylation found in testosterone treated rats may play role in
this phenomenon through the phosphorylation of the adapter protein APS inducing ubiquitination,
and consequent internalization and degradation of IRβ [35,36]. Although the hyperinsulinemia in
vitamin D deficiency and the possible increase in IRβ degradation induced by the elevated p-Akt/Akt
ratio in testosterone treatment may play role in lower IRβ density, further investigations are necessary
to clarify the involved mechanisms.
PCOS is associated with enhanced inflammatory activity and systemic oxidative and nitrative
stress [37]. In our experiment, Vitamin D deficiency alone increased NT staining in the ovaries,
whereas in the liver testosterone treatment had a similar effect. The role of mTOR and p-S6 pathway
has been previously shown to be involved in inflammatory processes leading to iNOS induction
and oxidative-nitrative stress [38]. S6 phosphorylation showed similar pattern as NT staining in our
experiments, although its changes did not reach significant level in all cases. Another experiment also
found significant NT increase in brain homogenates of vitamin D-deficient mice [39]. Surprisingly, in our
setting, D–T+ group showed no increase in NT staining. This could be explained by exhaustion of
nitrosative stress, furthermore in PCOS women, a significantly decreased serum level of arginine
and citrulline was measured, suggesting a lack of substrate for iNOS [40] and the consequential
protein nitration.
In our experiment, elevated expression of VDR is detected in both ovarian and liver tissues
of vitamin D deficient hyperandrogenic rats, which was prevented by vitamin D supplementation.
In spite of the generally accepted idea that vitamin D upregulates VDR expression [41], in recently
published experiments, an elevated VDR expression was detected in the heart tissue of vitamin D
deficient rats [42]. Moreover, decreased VDR mRNA levels were detected in the peripheral blood
mononuclear cells of vitamin D supplemented multiple sclerosis patients [43]. The effect of testosterone
on VDR expression was examined in a recent study, but they found no difference in the number of
VDR in porcine ovarian follicular cells after a 6 h testosterone treatment. However, disrupted coupling
with retinoid X receptor (RXR) was detected, causing an alteration in the transcriptional activity of
VDR [44]. Testosterone was also shown to increase the expression of vitamin D binding protein in
male rats [45]. Research involving prostate and ovarian cancer propose the potential role of androgen
receptor-coregulators, especially ARA70 (androgen receptor-associated protein 70), which seems to
be necessary for both androgen receptor (AR) and VDR transcriptional activity. High testosterone
levels lead to elevated AR activation, limiting the availability of ARA70 to coregulate the VDR/RXR
complex [46]. VDR/RXR complex stimulates sulfotransferase family 2A member 1 (SULT2A1) and
cytochrome P450 3A4 (CYP3A4) transcription, both of which are responsible for deactivating free
testosterone [47,48]. This way testosterone treatment may lead to the worsening of its own clearance
inducing a vicious circle of hyperandrogenism.
5. Conclusions
Altered insulin signaling and autophagosomal turnover in connection with nitrative stress was
found in the liver and ovarian tissues of our rat model of PCOS (Figure 6). Combined hyperandrogenism
and vitamin D deficiency led to decreased autophagy in the liver and altered insulin signaling in the
ovaries. Vitamin D supplementation could prevent the increase in Akt phosphorylation in the ovaries
that may contribute to the beneficial effect of vitamin D treatment on ovarian function. However, it could
not reverse the other adverse effects observed in the double challenged group. On the other hand,
vitamin D deficiency itself led to disrupted ovarian maturation and autophagy malfunction in the liver.
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Autophagy might be a key component in cellular changes induced by hyperandrogenism or vitamin D
deficiency that plays role in the development of NAFLD in PCOS patients.
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